GLAXOSMITHKLINE PLC ADR

NYSE: GSK (GSK plc)

Kemas kini terakhir: 2 hari lalu, 4:38PM

38.18

-0.33 (-0.86%)

Penutupan Terdahulu 38.51
Buka 38.37
Jumlah Dagangan 3,002,585
Purata Dagangan (3B) 5,382,942
Modal Pasaran 78,367,883,264
Harga / Pendapatan (P/E TTM) 18.27
Harga / Pendapatan (P/E Ke hadapan) 8.46
Harga / Jualan (P/S) 1.83
Harga / Buku (P/B) 3.97
Julat 52 Minggu
31.72 (-16%) — 44.67 (16%)
Tarikh Pendapatan 30 Jul 2025
Hasil Dividen (DY TTM) 2.03%
Margin Keuntungan 10.00%
Margin Operasi (TTM) 30.79%
EPS Cair (TTM) 2.09
Pertumbuhan Hasil Suku Tahunan (YOY) 2.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 55.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 134.99%
Nisbah Semasa (MRQ) 0.870
Aliran Tunai Operasi (OCF TTM) 6.74 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 5.16 B
Pulangan Atas Aset (ROA TTM) 6.55%
Pulangan Atas Ekuiti (ROE TTM) 27.09%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok GSK plc Bercampur Menaik

AISkor Stockmoo

-0.3
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata -0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GSK 78 B 2.03% 18.27 3.97
JNJ 375 B 2.38% 17.35 4.81
ABBV 334 B 3.37% 80.54 237.28
PFE 144 B 5.00% 18.39 1.58
BMY 95 B 3.88% 17.51 5.57
LLY 701 B 0.53% 63.68 44.16

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.06%
% Dimiliki oleh Institusi 18.20%

Pemilikan

Nama Tarikh Syer Dipegang
Jtc Employer Solutions Trustee Ltd 31 Mar 2025 15,260,368
Equity Investment Corp 31 Mar 2025 4,174,189
Tarikh Jenis Butiran
24 Jun 2025 Pengumuman FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
18 Jun 2025 CNBC FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
16 Jun 2025 Pengumuman GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
09 Jun 2025 CNBC FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
02 Jun 2025 Pengumuman Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
22 May 2025 Pengumuman Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
09 May 2025 Pengumuman GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
16 Apr 2025 Pengumuman AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
16 Apr 2025 Pengumuman GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
11 Apr 2025 Pengumuman Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment
09 Apr 2025 Pengumuman GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
Papar semua
Hasil Dividen (DY TTM) 2.03%
Purata Hasil Dividen 3T 3.09%
Nisbah Pembayaran 79.84%
Jangkaan Pembayaran Dividen Seterusnya Oct 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Nov 2024 30 Oct 2024 09 Jan 2025 0.389052 Tunai
16 Aug 2024 31 Jul 2024 10 Oct 2024 0.385671 Tunai
16 May 2024 01 May 2024 11 Jul 2024 0.376185 Tunai
22 Feb 2024 01 Feb 2024 11 Apr 2024 0.4060608 Tunai
16 Nov 2023 01 Nov 2023 11 Jan 2024 0.3397772 Tunai
17 Aug 2023 26 Jul 2023 12 Oct 2023 0.361256 Tunai
18 May 2023 26 Apr 2023 13 Jul 2023 0.347508 Tunai
23 Feb 2023 01 Feb 2023 13 Apr 2023 0.3403867 Tunai
17 Nov 2022 02 Nov 2022 12 Jan 2023 0.3171217 Tunai
18 Aug 2022 27 Jul 2022 06 Oct 2022 0.390832 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.389 1 1.02
2024 1.51 4 4.46
2023 1.37 4 3.69
2022 0.391 1 1.11
39.8139.8139.1339.1338.4438.4437.7637.7637.0837.08Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.6000.6000.4000.4000.2000.2000.0000.000-0.200-0.200MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda